Literature DB >> 10696750

Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema.

J M Jumper1, S N Embabi, C A Toth, I I McCuen BW, D L Hatchell.   

Abstract

BACKGROUND: Tangential traction in the macula from a thickened posterior hyaloid of the vitreous has been implicated as a cause of diffuse diabetic macular edema. Vitrectomy with peeling of the posterior hyaloid has been shown to reduce retinovascular leakage and improve vision in select patients. We report a clinicopathologic correlation using electron microscopy and electron immunocytochemistry to characterize the membrane infiltrating the posterior hyaloid in two such patients.
METHODS: Two patients presented with vision loss associated with diffuse diabetic macular edema and an attached, thickened, and taut posterior hyaloid. The patients underwent vitrectomy with peeling of the posterior hyaloid. The premacular posterior hyaloid specimens then were analyzed by electron microscopy with immunocytochemical staining for cytokeratin and glial fibrillary acidic protein.
RESULTS: Both posterior hyaloid specimens contained collagen and a large cellular component. Immunogold labeling showed cells positive for glial fibrillary acidic protein or cytokeratin. With double labeling, no cells expressed both proteins simultaneously. Clinically, both patients had vision improvement and macular edema resolution after surgery.
CONCLUSIONS: The thickened, taut posterior hyaloid observed in our patients with diabetic macular edema contained cells of glial and epithelial origin. This cellular infiltration may contribute to abnormal vitreomacular adherence and could play a role in the pathogenesis of macular edema in some patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696750     DOI: 10.1097/00006982-200001000-00012

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Perifoveal vitreous detachment and its macular complications.

Authors:  Mark W Johnson
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 2.  Diabetic macular edema: what is focal and what is diffuse?

Authors:  David J Browning; Michael M Altaweel; Neil M Bressler; Susan B Bressler; Ingrid U Scott
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

Review 3.  Visualizing vitreous in vitrectomy by triamcinolone.

Authors:  Taiji Sakamoto; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-20       Impact factor: 3.117

4.  Preservation of structure and immunoreactivity at the vitreoretinal interface of the rabbit eye.

Authors:  Bruce A Pfeffer; Steven A Bernstein; Stephen P Bartels
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-20       Impact factor: 3.117

5.  Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities.

Authors:  Dan Yoon; Irene Rusu; Irene Barbazetto
Journal:  Int Ophthalmol       Date:  2013-11-22       Impact factor: 2.031

6.  Systemic and vitreous biomarkers - new insights in diabetic retinopathy.

Authors:  Bernardete Pessoa; João Heitor; Constança Coelho; Magdalena Leander; Pedro Menéres; João Figueira; Angelina Meireles; Melo Beirão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-24       Impact factor: 3.535

Review 7.  The Vitreomacular Interface in Diabetic Retinopathy.

Authors:  Daniel Agarwal; Rachel Gelman; Claudia Prospero Ponce; William Stevenson; John B Christoforidis
Journal:  J Ophthalmol       Date:  2015-09-03       Impact factor: 1.909

8.  Hyperreflective Membrane at the Vitreoretinal Interface in Diabetic Macular Edema: A Finding in Ultra-High-Resolution Optical Coherence Tomography.

Authors:  Iori Wada; Shintaro Nakao; Mitsuru Arima; Keijiro Ishikawa; Muneo Yamaguchi; Yoshihiro Kaizu; Haruka Sekiryu; Kenichiro Mori; Kohei Kiyohara; Atsunobu Takeda; Tatsuro Ishibashi; SriniVas R Sadda; Koh-Hei Sonoda
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.